GSK is fur­ther delv­ing in­to the car­diometa­bol­ic space — and deep­en­ing its re­la­tion­ship with Chi­na biotechs — in a $1 bil­lion biobucks deal with an...

Two sci­en­tists think they've solved a tech­ni­cal prob­lem that has kept the mR­NA rev­o­lu­tion from reach­ing its full po­ten­tial.

Now, they're launch­ing Parcel­Bio with $13...

Ava­lo Ther­a­peu­tics’ come­back bid surged for­ward Tues­day af­ter­noon, as the im­munol­o­gy biotech se­cured a mid-stage tri­al win in an in­flam­ma­to­ry skin dis­or­der.

Ava­lo saidthat...

🚀 Madri­gal Phar­ma­ceu­ti­cal­s' MASH drug beats ex­pec­ta­tions: The biotech’s Rezd­if­fra sales came in at $311 mil­lion for the first quar­ter, sur­pass­ing an­a­lysts’ pro­jec­tions by about...